Sanofi Consumer Healthcare India Limited announced the designation of two senior executives as Senior Management Personnel following a board meeting held on February 25, 2026. The decision reflects the company's strategic focus on strengthening its leadership structure across key operational areas.

Board Decision and Regulatory Compliance

The Board of Directors, acting on recommendations from the Nomination & Remuneration Committee, designated Ms. Nupur Gurbaxani and Mr. Viral Shah as Senior Management Personnel effective February 25, 2026. The board meeting commenced at 2:00 p.m. and concluded at 5:20 p.m.

The company made this disclosure pursuant to Regulation 30 read with Para A(7) of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was sent to both BSE Limited and National Stock Exchange of India Limited as per regulatory requirements.

Senior Management Personnel Details

Ms. Nupur Gurbaxani - Brand & Innovation Leadership

Ms. Gurbaxani serves as Director of Brand & Innovation and has been instrumental in driving the company's brand penetration turnaround since joining in July 2024. She brings a consumer-centric approach with sharp insights, innovative campaigns, and digital-first strategies.

An alumna of NMIMS, she possesses over 18 years of extensive experience across leading consumer and healthcare companies including Godrej Consumer Products, Novartis, and Abbott Nutrition. Her expertise positions her to play a critical role in the company's brand transformation and future growth initiatives.

Mr. Viral Shah - Manufacturing Excellence

Mr. Shah holds the position of Director of External Manufacturing and has been driving key infrastructure development initiatives since joining in May 2024. His focus areas include developing partnerships and capabilities to support the company's "Make In India" strategy across product lines.

A graduate of KJ Somaiya Institute of Management, he brings over 20 years of manufacturing and pharmaceutical industry experience from prominent organizations including Torrent, Ranbaxy Laboratories, Merck & Co., and Bayer. His strategic insight and industry expertise are expected to strengthen manufacturing capabilities and accelerate export growth from India.

Strategic Implications

The designation of these executives as Senior Management Personnel underscores Sanofi Consumer Healthcare India's commitment to strengthening its operational leadership. Both appointments align with the company's strategic priorities in brand innovation and manufacturing excellence, positioning the organization for enhanced market performance and growth acceleration. The formal notification to stock exchanges demonstrates the company's adherence to regulatory compliance and transparency standards.

Sanofi Consumer Healthcare India Limited has announced outstanding financial results for Q4FY25 and FY25, demonstrating exceptional growth across all key performance metrics. The consumer healthcare company reported strong results following the Board meeting held on February 25, 2026, with audited standalone financial statements showing remarkable improvement in profitability and revenue generation under Regulation 30 of SEBI Listing Obligations.

Q4FY25 Performance Highlights

The fourth quarter performance continued the strong momentum, with quarterly results showing exceptional growth patterns across key metrics, maintaining the positive trajectory throughout FY25.

Annual Financial Performance Overview

The company's full-year results reveal substantial improvement across all financial parameters, reflecting strong market performance and effective business execution strategies.

Management Commentary and Strategic Outlook

Commenting on the Q4FY25 results, Himanshu Bakshi, Managing Director, emphasized the strength of the core portfolio and disciplined execution of growth agenda. The domestic business delivered healthy double-digit growth for two successive quarters, complemented by strong contributions from export markets. The company remains focused on reinforcing brand fundamentals and driving operational excellence to unlock sustainable growth.

Amit Jain, Chairman, highlighted that the full-year performance reflects strategic strength and disciplined execution by teams. The company drove sustained growth, deepened portfolio penetration, and accelerated digital transformation, delivering meaningful outcomes for stakeholders.

Board Decisions and Dividend Declaration

The Board of Directors has recommended a final dividend of ₹75 per equity share of face value ₹10 each for FY25, subject to shareholder approval at the upcoming Annual General Meeting. The Board also approved the re-appointment of M/s. Kishore Bhatia & Associates, Cost Accountants as Cost Auditor for FY26, subject to shareholder ratification.

Business Recovery and Product Portfolio

The company successfully navigated product recall challenges from the previous year, with successful relaunches of key products including Depura Adult, Combiflam Suspension, Allegra Suspension, and Depura Kids across different quarters of FY25. This recovery contributed significantly to the improved financial performance and market position, supporting the strong domestic sales growth of 23% in Q4FY25.

The annual results demonstrate Sanofi Consumer Healthcare's resilient business model and strong execution capabilities, positioning the company well for continued growth in the consumer healthcare segment with robust financial fundamentals and operational excellence.